• Clinical Insights: July 14, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval No new updates.   New Indication Approval Blincyto® (blinatumomab) – New Expanded Indication Approval – July 11, 2017 – Amgen announced that the U.S. Food and Drug… Read more »

  • CEO Fenton Markevich on the Importance of 340B

    President and CEO Fenton Markevich was recently featured in 340B Health’s 340B Chronicle, News from the 340B Health PAC. In this highlight, Fenton answered questions pertaining to his personal commitment and RxStrategies’ commitment to the 340B community and the 340B program, as well as the significance of contributing to the 340B Health PAC. Read the… Read more »

  • Clinical Insights: July 7, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Endari™ (L-glutamine oral powder) – July 7, 2017 – The U.S. Food and Drug Administration approved Endari (L-glutamine oral powder) for patients age five years and older… Read more »

  • Ready to Connect at the 340B Coalition Summer Conference!

    RxStrategies is proud to be a Pinnacle Leader Sponsor of the 2017 340B Coalition Summer Conference, July 10-12. Our team will be connecting with industry leaders to gain insight and discuss the latest 340B Program developments during this highly attended conference. RxStrategies’ 340BPlus™ CompliancePlus (Self-Audit Tool), Dashboard Analytics, Contract Pharmacy, Split Billing and Specialty Pharmacy solutions are key to a… Read more »

  • Clinical Insights: June 30, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval No new updates.   New Indication Approval No new updates.   New Drug Shortage June 21, 2017 Cromolyn Sodium Inhalation Solution, USP (Currently in Shortage) New… Read more »

  • Connect with us at the FACHC 2017 Annual Meeting

      The RxStrategies team will be connecting with industry leaders July 16-19 in St. Petersburg, Florida for the Florida Association of Community Health Centers 2017 Annual Meeting and Education Summit. At the conference, we will be linking with professionals dedicated to providing quality community-based health care programs in Florida and discussing integrated 340B program management… Read more »

  • Clinical Insights: June 23, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Bevyxxa™ (betrixaban) – June 23, 2017 – The U.S. Food and Drug Administration approved betrixaban (Bevyxxa™, Portola) for the prophylaxis of venous thromboembolism (VTE) in adult patients… Read more »

  • Clinical Insights: June 16, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Fibryna® (fibrinogen – [human]) – June 7, 2017 – A human fibrinogen concentrate indicated for the treatment of acute bleeding episodes in adults and adolescents with congenital… Read more »

  • Clinical Insights: June 2, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Rebinyn® (Coagulation Factor IX (Recombinant), GlycoPEGylated) – May 31, 2017 – Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application… Read more »